KRAS and neoplasm: Emerging clinical data suggest that intra-tumor let-7a expression correlates with tumor response and overall survival in metastatic colorectal cancer patients receiving epidermal growth factor (EGFR) targeting agents in both KRAS wild-type and mutant populations [17].